FREMONT, Calif. — Shares of Alamar Biosciences Inc. surged 15.90% to $37.10 in Thursday trading, adding $5.09, pushing the precision proteomics company's stock close to its 52-week high as investor interest continues building following a string of recent analyst upgrades, strategic partnerships and appearances at major healthcare investor conferences.

The rally lifts Alamar shares near the top of a 52-week trading range that has spanned from $17.00, the price at which the company priced its initial public offering in April, to a high of $38.54. Alamar debuted on the Nasdaq on April 20, with shares jumping 33% on their first day of trading and valuing the precision protein biomarker detection company at approximately $1.53 billion at the time. The company's IPO raised roughly $219.9 million in gross proceeds after pricing 12.9 million shares, including the full exercise of the underwriters' option, at $17 per share, the high end of its marketed range.

Alamar's stock has continued to draw attention from Wall Street analysts in the months since its public debut. Leerink initiated coverage of the company with an Outperform rating and a $35 price target, with the firm's thesis centered on what it described as Alamar's differentiated, highly automated ARGO HT instrument and its underlying NULISA technology platform. Stifel more recently raised its own price target on Alamar shares to $32 from $28, according to........

© International Business Times